Literature DB >> 18565357

[Neurological damage of brain tumor therapy].

D Ricard1, T De Greslan, C Soussain, P Bounolleau, M Sallansonnet-Froment, J-M Delmas, H Taillia, N Martin-Duverneuil, J-L Renard, K Hoang-Xuan.   

Abstract

Damage to the central nervous system induced by treatment of brain tumors is common and impairs the patient quality-of-life. Neurotoxicity is induced by synergistic effects of different cytotoxic treatments such as radiotherapy and chemotherapies administered concurrently or sequentially. Recent progress in the management of brain tumors has led to new neurotoxicities. The growing concern about the neuropsychological performance of patients has disclosed another type of brain damage which has been largely neglected to date. Neurological toxicity can be acute, requiring dose adaptation or a change of drugs. But it also often occurs late and can be irreversible. To date, treatments have been ineffective. The early diagnosis of neurotoxicity is thus a major challenge. Numerous clinical studies suggest an individual sensitivity which is not only related to age or vascular status, but also to genetic predisposition that remains to be detailed. Understanding the mechanisms of personal susceptibilities would be helpful in designing more tailored treatments. In this review we address the question of adverse effects of brain radiation as well as those of chemotherapy protocols which are particularly toxic for the central nervous system that is, methotrexate, platin and aracytin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565357     DOI: 10.1016/j.neurol.2008.03.014

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

Review 1.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

2.  [Management of cerebral radionecrosis: experience in the Department of Neurology at the Mohammed V Military Teaching Hospital].

Authors:  Amine Raggabi; Ahmed Bourazza; Issam Lalya
Journal:  Pan Afr Med J       Date:  2019-07-11

3.  Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma.

Authors:  Ni Fan; Lu Zhang; Xiaoping Xu; Bobin Chen; Chen Zhu; Pei Li; Zi Chen; Tianling Ding; Yan Ma; Yan Yuan; Zhiguang Lin
Journal:  Oncotarget       Date:  2017-03-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.